613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster III

Efficacy of upfront blinatumomab combined with reduced-intensity chemotherapy for newly diagnosed adult Philadelphia chromosome-negative B-lineage acute lymphoblastic leukemia: Interim analysis of two prospective studies of JSCT

Short duration blinatumomab for residual disease eradication as a bridge to transplant in B ALL Pediatric and adult outcomes in a resource limited context

Blinatumomab following reduced intensity induction chemotherapy in Chinese children with intermediate or high risk B cell precursor acute lymphoblastic leukemia

Long term outcomes of a chemotherapy free regimen of concomitant blinatumomab and inotuzumab ozogamicin in older patients with Philadelphia negative B cell acute lymphoblastic leukemia

Blinatumomab combined with low dose chemotherapy and TKI as first line induction for newly diagnosed ph b ALL Improved efficacy and reduced toxicity

High dose methotrexate consolidation prior to autologous HSCT in b ALL A decade long retrospective analysis of survival and toxicity outcomes

Efficacy and safety of a retreatment with inotuzumab ozogamicin in adult patients with relapsed refractory acute lymphoblastic leukemia A Campus ALL study

Relapsed acute lymphoblastic leukemia treated with venetoclax and navitoclax Results of the raven study in children and young adults with relapsed refractory ALL

A phase I study of venetoclax in combination with multiagent cytotoxic chemotherapy for children and adolescents with relapsed or refractory acute lymphoblastic leukemia or mixed phenotype acute leukemia Results of the dose determination cohort

Outcome of adult B precursor acute lymphoblastic leukemia ALL treated with blinatumomab in addition to chemotherapy independent of MRD First results from the national GMALL registry

Integrating next generation sequencing disease evaluation and PCR based CAR T cell tracking to guide decision making in a real world cohort of pediatric B cell ALL patients

Toxicities on the E1910 phase III randomized trial of blinatumomab plus chemotherapy in adults with BCR ABL 1 negative acute lymphoblastic leukemia

Impact of asparaginase discontinuation on outcomes in pediatric B cell precursor acute lymphoblastic leukemia Post hoc analysis of the JCCG ALL B12 Study

Chimeric antigen receptor CAR T cell persistence at month 3 predicts clinical outcomes in adult patients with relapsed refractory B cell acute lymphoblastic leukemia R R B ALL treated with obecabtagene autoleucel obe cel

Efficacy of single agent subcutaneous blinatumomab in adults with relapsed refractory R R B cell acute lymphoblastic leukemia B ALL Results from a phase 1 2 dose expansion study with extended follow up